| Vortioxetine effectiveness overview for the treated MDE patients in Saudi Arabia |
Ongoing |
BRINTELLIX 20 mg film-coated tablet/ BRINTELLIX 10 mg film-coated tablet |
4 |
18620N |
King Abdulaziz University Hospital (Jeddah), Saudi German Hospital (Jeddah), Dr. Erfan & Bagedo General Hospital (Jeddah), University Medical Center (Riyadh), Psych care Center (Riyadh), Dr. Sulaiman Al-Habib Medical Group Olaya (Riyadh), Al Moosa Specialized Hospital (al ahsa), King Fahad Medical City (Riyadh), Almana Hospital (Dammam), King Abdullah Medical Complex (Jeddah), Jeddah psychiatric hospital, Elite Medical Complex (Makkah) |
| "Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)" |
Ongoing |
• Ceftriaxone • Piperacillin Tazobactam • Azithromycin • Interferon β1-a • Hydrocortisone sodium suc.• Hydroxychloroquine • OSELTAMIVIR • Lopinavir-Ritonavir |
3 |
CT20/001/R |
King Abdulaziz Medical City NG (Riyadh) |
| A multicentre non-interventional study to assess the real-world effectiveness of Ocrelizumab in patients with relapsing or primary progressive multiple sclerosis – The MuSicalE STUDY |
Ongoing |
Ocrelizumab (Ocrevus) |
4 |
MN39889 |
King Abdulaziz Medical City NG (Riyadh) |
| A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19 |
Ongoing |
• Favipiravir• HYDROXYCHLOROQUINE SULPHATE |
3 |
RC20/174/R |
King Abdulaziz Medical City NG (Riyadh) |
| A Trial of Favipiravir in Adults with Mild Coronavirus Disease Covid-19 |
Ongoing |
Favipiravir |
3 |
RC20/220/R |
King Abdulaziz Medical City NG (Riyadh) |
| An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care |
Ongoing |
• Hydroxychloroquine sulphate• CHLOROQUINE PHOSPHATE• Lopinavir/Ritonavir • Remdesivir• Interferon beta-1b |
3 |
version 8 |
Qatif Central Hospital, Dammam Medical Complex, Ohud hospital (Medina), Al-Noor Specialist Hospital (Makkah), Prince Mohammad bin Abdulaziz hospital (Riyadh) |
| A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 |
Ongoing |
Convalescent Plasma |
2 |
20-COVID-19-01M |
King Fahad Specialist Hospital (Dammam), International Medical Center (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Abdulaziz Hospital NG (Al Ahsa), Prince Mohammad bin Abdulaziz Hospital NG (Medina), Qatif Central Hospital, Dammam Medical Complex, King Fahad Medical City (Riyadh), King Saud Medical City (Riyadh), King Abdullah Medical City (Makkah), Al-Noor Specialist Hospital (Makkah), King Abdullah Medical Complex (Jeddah), Ohud hospital (Medina), King Fahad Genaral Hospital (Medina), Aseer Central Hospital (Abha) |
| An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2) |
Ongoing |
A4250 |
3 |
A4250-008 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A phase II, multicenter, open label study of treatment escalation to ACVD (Adriamycin, Cyclophosphamide, Vinblastine and Dacarbazine) and Brentuximab-Vedotin in advanced-stage Hodgkin Lymphoma patients with a positive interim PET scan after 2 ABVD cycles (OPTIMIST study) |
Ongoing |
• DOXORUBICIN HYDROCHLORIDE• CYCLOPHOSPHAMIDE• VINBLASTINE SULPHATE • DACARBAZINE• BRENTUXIMAB VEDOTIN |
2 |
RC16/150 |
King Abdulaziz Medical City NG (Riyadh) |
| "ALL SCTped 2012 FORUMAllogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia" |
Completed |
• BUSULFAN• FLUDARABINE PHOSPHATE• ETOPOSIDE |
3 |
CT17/016/R |
King Abdulaziz Medical City NG (Riyadh) |
